551
|
Setta-Kaffetzi N, Simpson M, Navarini A, Patel V, Lu HC, Allen M, Duckworth M, Bachelez H, Burden A, Choon SE, Griffiths C, Kirby B, Kolios A, Seyger M, Prins C, Smahi A, Trembath R, Fraternali F, Smith C, Barker J, Capon F. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet 2014; 94:790-7. [PMID: 24791904 DOI: 10.1016/j.ajhg.2014.04.005] [Citation(s) in RCA: 125] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Accepted: 04/09/2014] [Indexed: 11/26/2022] Open
Abstract
Adaptor protein complex 1 (AP-1) is an evolutionary conserved heterotetramer that promotes vesicular trafficking between the trans-Golgi network and the endosomes. The knockout of most murine AP-1 complex subunits is embryonically lethal, so the identification of human disease-associated alleles has the unique potential to deliver insights into gene function. Here, we report two founder mutations (c.11T>G [p.Phe4Cys] and c.97C>T [p.Arg33Trp]) in AP1S3, the gene encoding AP-1 complex subunit σ1C, in 15 unrelated individuals with a severe autoinflammatory skin disorder known as pustular psoriasis. Because the variants are predicted to destabilize the 3D structure of the AP-1 complex, we generated AP1S3-knockdown cell lines to investigate the consequences of AP-1 deficiency in skin keratinocytes. We found that AP1S3 silencing disrupted the endosomal translocation of the innate pattern-recognition receptor TLR-3 (Toll-like receptor 3) and resulted in a marked inhibition of downstream signaling. These findings identify pustular psoriasis as an autoinflammatory phenotype caused by defects in vesicular trafficking and demonstrate a requirement of AP-1 for Toll-like receptor homeostasis.
Collapse
|
552
|
de Veer SJ, Furio L, Harris JM, Hovnanian A. Proteases and proteomics: Cutting to the core of human skin pathologies. Proteomics Clin Appl 2014; 8:389-402. [DOI: 10.1002/prca.201300081] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Revised: 10/22/2013] [Accepted: 11/07/2013] [Indexed: 12/20/2022]
Affiliation(s)
- Simon J. de Veer
- Université Paris Descartes - Sorbonne Paris Cité; Paris France
- INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute; Paris France
- Institute of Health and Biomedical Innovation; Queensland University of Technology; Brisbane Australia
| | - Laetitia Furio
- Université Paris Descartes - Sorbonne Paris Cité; Paris France
- INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute; Paris France
| | - Jonathan M. Harris
- Institute of Health and Biomedical Innovation; Queensland University of Technology; Brisbane Australia
| | - Alain Hovnanian
- Université Paris Descartes - Sorbonne Paris Cité; Paris France
- INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute; Paris France
- Department of Genetics; Necker Hospital for Sick Children; Paris France
| |
Collapse
|
553
|
Posso-De Los Rios CJ, Pope E. New insights into pustular dermatoses in pediatric patients. J Am Acad Dermatol 2014; 70:767-773. [DOI: 10.1016/j.jaad.2013.11.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2013] [Revised: 10/02/2013] [Accepted: 11/04/2013] [Indexed: 11/29/2022]
|
554
|
Federici S, Gattorno M. A practical approach to the diagnosis of autoinflammatory diseases in childhood. Best Pract Res Clin Rheumatol 2014; 28:263-76. [DOI: 10.1016/j.berh.2014.05.005] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
555
|
Bachelez H, Viguier M, Tebbey PW, Lowes M, Suárez-Fariñas M, Costanzo A, Nestle FO. The mechanistic basis for psoriasis immunopathogenesis: translating genotype to phenotype. Report of a workshop, Venice, 2012. Br J Dermatol 2014; 169:283-6. [PMID: 23941252 DOI: 10.1111/bjd.12347] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/21/2013] [Indexed: 01/04/2023]
Abstract
The International Psoriasis Council, a global nonprofit organization dedicated to advancing psoriasis research and treatment, led an initiative to better define the pathogenic mechanisms that constitute psoriasis. In September 2012, a workshop was held at the 42nd Annual European Society for Dermatological Research in Venice, Italy. By assembling a panel of global dermatology and immunology experts, the objective was to evaluate the current status of the science explaining the mechanism of disease in psoriasis, e.g. dysregulation of the skin immune system and perturbations of epidermal homeostasis. The workshop consisted of four oral presentations, which addressed key topics in psoriasis, delivered by Hervé Bachelez (Paris, France), Antonio Costanzo (Rome, Italy), Michelle Lowes (New York, NY, U.S.A.) and Frank Nestle (London, U.K.). A global expert panel was assembled to stimulate dialogue and debate: Kevin Cooper (Cleveland, OH, U.S.A.), Michel Gilliet (Lausanne, Switzerland), Joerg Prinz (Munich, Germany), Martin Röcken (Tubingen, Germany), Jens Schroeder (Kiel, Germany), Manuelle Viguier (Paris, France), Mayte Suárez-Fariñas (New York, NY, U.S.A.) and Cristina Zielinski (Berlin, Germany). Collectively, the presentations demonstrated the significant advances in understanding immune regulation that have occurred over the past decade by virtue of the study of psoriasis subtypes, phenotypic manifestations and genetic associations. Elucidating the pathogenic and genetic basis of psoriasis holds the promise of a complete understanding of disease mechanisms, predictors of treatment response, novel drug development strategies and customized therapeutic regimens for the individual patient.
Collapse
Affiliation(s)
- H Bachelez
- Department of Dermatology, Saint-Louis Hospital, Sorbonne Paris Cité University Paris Diderot, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
556
|
Abstract
While autoimmunity as cause of disease is well-established, other categories of immune-mediated diseases that are not produced by targeting of self-antigens by antibodies is in the process of being described. These so-called autoinflammatory diseases arise when an inappropriate activation of antigen-independent mechanisms occurs. Autoinflammatory diseases course with recurrent attacks of fever and multisystemic inflammation; however, the skin may also be affected by a variety of inflammatory manifestations that often alert the clinician about the presence of an autoinflammatory disease. Recognizing the cutaneous features of these syndromes will aid for prompt diagnosis and early treatment that is key for the quality of life and survival of the affected patients. In this paper, we focus on the skin manifestations of autoinflammatory diseases in children, which is the usual period of appearing of the first symptoms and signs.
Collapse
|
557
|
Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2014; 39:1003-18. [PMID: 24332029 DOI: 10.1016/j.immuni.2013.11.010] [Citation(s) in RCA: 1327] [Impact Index Per Article: 132.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Accepted: 11/20/2013] [Indexed: 12/14/2022]
Abstract
Interleukin-1 (IL-1) is a central mediator of innate immunity and inflammation. The IL-1 family includes seven ligands with agonist activity (IL-1α and IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ), three receptor antagonists (IL-1Ra, IL-36Ra, IL-38), and an anti-inflammatory cytokine (IL-37). Members of the IL-1 Receptor (IL-1R) family include six receptor chains forming four signaling receptor complexes, two decoy receptors (IL-1R2, IL-18BP), and two negative regulators (TIR8 or SIGIRR, IL-1RAcPb). A tight regulation via receptor antagonists, decoy receptors, and signaling inhibitors ensures a balance between amplification of innate immunity and uncontrolled inflammation. All cells of the innate immune system express and/or are affected by IL-1 family members. Moreover, IL-1 family members play a key role in the differentiation and function of polarized innate and adaptive lymphoid cells. Here we will review the key properties of IL-1 family members, with emphasis on pathways of negative regulation and orchestration of innate and adaptive immunity.
Collapse
Affiliation(s)
- Cecilia Garlanda
- Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, Italy
| | - Charles A Dinarello
- Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO 80045, USA; Department of Medicine, Radboud University Medical Center, Nijmegen 6500 HC, The Netherlands
| | - Alberto Mantovani
- Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, Italy; BIOMETRA Department, Università degli Studi di Milano, 20133 Milano, Italy.
| |
Collapse
|
558
|
Affiliation(s)
- C E M Griffiths
- The Dermatology Centre, Salford Royal Hospital, The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K..
| |
Collapse
|
559
|
Abstract
Spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases whose main clinical feature is inflammation of the axial spine. Articular, periarticular, and extra-articular manifestations can also occur, depending on the type of spondyloarthritis. The most common clinical subsets of SpA are ankylosing spondylitis (AS) and psoriatic arthritis (PsA). SpA is a major health challenge given the propensity to affect young adults and the potential requirement for lifelong treatment. Although the precise etiology of SpA is unknown, there is mounting evidence that these diseases are a result of complex interplay of genetic, environmental, and immunological factors. In this review on SpA, we will discuss genetic variants with genome-wide significance, highlight potential clinical application of genetic variants, and discuss challenges in further elucidating the genetic basis of SpA.
Collapse
|
560
|
Sugiura K, Haruna K, Suga Y, Akiyama M. Generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist successfully treated with granulocyte and monocyte adsorption apheresis. J Eur Acad Dermatol Venereol 2014; 28:1835-6. [DOI: 10.1111/jdv.12383] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- K. Sugiura
- Department of Dermatology; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - K. Haruna
- Department of Dermatology; Juntendo University Urayasu Hospital; Urayasu Japan
| | - Y. Suga
- Department of Dermatology; Juntendo University Urayasu Hospital; Urayasu Japan
| | - M. Akiyama
- Department of Dermatology; Nagoya University Graduate School of Medicine; Nagoya Japan
| |
Collapse
|
561
|
Sugiura K, Shoda Y, Akiyama M. Generalized Pustular Psoriasis Triggered by Amoxicillin in Monozygotic Twins with Compound Heterozygous IL36RN Mutations: Comment on the Article by Navarini et al. J Invest Dermatol 2014; 134:578-579. [DOI: 10.1038/jid.2013.354] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
562
|
Failure to find evidence for deletion of LCE3C and LCE3B genes at PSORS4 contributing to psoriasis susceptibility in Tunisian families. ACTA ACUST UNITED AC 2014; 62:34-7. [PMID: 24485035 DOI: 10.1016/j.patbio.2013.10.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2012] [Accepted: 10/08/2013] [Indexed: 11/24/2022]
Abstract
BACKGROUND Recently, it has been shown that a deletion in the late cornified envelope (LCE) gene cluster (LCE3C_LCE3B-del) is associated with susceptibility to psoriasis in European and Asian populations. However, no study of this deletion has been performed in the North African population. The aim of the present study was to investigate whether this deletion is associated with familial psoriasis in Tunisian population. METHODS A total of 34 patients and 55 healthy individuals were recruited from 7 multiplex families and a PCR assay was used to determine the association of this deletion. Its effect on susceptibility to psoriasis was assessed using the PDT program. RESULTS We failed to detect any evidence of association between LCE3C_LCE3B-del and psoriasis in Tunisian families. No epistasic effect was found between the deletion and PSORS1 locus. CONCLUSIONS These findings indicate that the LCE3C_LCE3B-del does not contribute in a major way to psoriasis susceptibility in Tunisian families.
Collapse
|
563
|
Wolf J, Ferris LK. Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: a patent evaluation of WO2013074569. Expert Opin Ther Pat 2014; 24:477-9. [PMID: 24456078 DOI: 10.1517/13543776.2014.881473] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The IL-36 family of cytokines and receptors seems to play a role in the pathogenesis of both pustular psoriasis, and the much more common variant, plaque-type psoriasis. Human skin biopsies from patients with psoriasis show overexpression of IL-36 and mice that lack the inhibitory IL-36 receptor (IL-36Ra) antagonist develop psoriasis, suggesting that signaling through the IL-36R may drive the skin lesions of psoriasis. Currently, no drugs targeting IL-36 are used in the treatment of psoriasis. The patent WO2013074569 describes an antibody to the IL-36R that is proposed as a potential therapy for psoriasis.
Collapse
Affiliation(s)
- Joel Wolf
- University of Pittsburgh School of Medicine , 5th Floor, Pittsburgh, PA 15213 , USA
| | | |
Collapse
|
564
|
Abstract
Autoinflammatory diseases represent an expanding spectrum of genetic and non-genetic inflammatory diseases characterized by recurrent episodes of fever and systemic inflammation affecting the eyes, joints, skin, and serosal surfaces. Thus, these syndromes are recognized as disorders of innate immunity. Confirming this view, most autoinflammatory diseases are uniquely responsive to IL-1β blockade. Although many autoinflammatory diseases have a genetic cause, increasing evidence indicates that the degree of cell stress concurs to the severity of the disease phenotype. In this mini-review, I will discuss the recent advances on pathogenesis, pathophysiology and therapeutic approaches in autoinflammatory syndromes.
Collapse
|
565
|
Christophers E, Metzler G, Röcken M. Bimodal immune activation in psoriasis. Br J Dermatol 2014; 170:59-65. [DOI: 10.1111/bjd.12631] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/11/2013] [Indexed: 12/12/2022]
Affiliation(s)
| | - G. Metzler
- Department of Dermatology; Eberhard Karls University of Tübingen; Tübingen Germany
| | - M. Röcken
- Department of Dermatology; Eberhard Karls University of Tübingen; Tübingen Germany
| |
Collapse
|
566
|
Christophers E. Psoriasis: heterogeneity, innate immunity and comorbidities. ACTA ACUST UNITED AC 2014. [DOI: 10.1586/edm.12.11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
567
|
Berki DM, Mahil SK, David Burden A, Trembath RC, Smith CH, Capon F, Barker JN. Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris. J Invest Dermatol 2014; 134:271-273. [PMID: 23792462 DOI: 10.1038/jid.2013.285] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Dorottya M Berki
- Division of Genetics and Molecular Medicine, King's College London, London, UK
| | - Satveer K Mahil
- Division of Genetics and Molecular Medicine, King's College London, London, UK
| | - A David Burden
- Department of Dermatology, University of Glasgow, Glasgow, UK
| | - Richard C Trembath
- Division of Genetics and Molecular Medicine, King's College London, London, UK; Queen Mary, University of London, Barts and The London School of Medicine and Dentistry, London, UK
| | - Catherine H Smith
- Division of Genetics and Molecular Medicine, King's College London, London, UK
| | - Francesca Capon
- Division of Genetics and Molecular Medicine, King's College London, London, UK.
| | - Jonathan N Barker
- Division of Genetics and Molecular Medicine, King's College London, London, UK.
| |
Collapse
|
568
|
Abstract
The skin is the front line of defense against insult and injury and contains many epidermal and immune elements that comprise the skin-associated lymphoid tissue (SALT). The reaction of these components to injury allows an effective cutaneous response to restore homeostasis. Psoriasis vulgaris is the best-understood and most accessible human disease that is mediated by T cells and dendritic cells. Inflammatory myeloid dendritic cells release IL-23 and IL-12 to activate IL-17-producing T cells, Th1 cells, and Th22 cells to produce abundant psoriatic cytokines IL-17, IFN-γ, TNF, and IL-22. These cytokines mediate effects on keratinocytes to amplify psoriatic inflammation. Therapeutic studies with anticytokine antibodies have shown the importance of the key cytokines IL-23, TNF, and IL-17 in this process. We discuss the genetic background of psoriasis and its relationship to immune function, specifically genetic mutations, key PSORS loci, single nucleotide polymorphisms, and the skin transcriptome. The association between comorbidities and psoriasis is reviewed by correlating the skin transcriptome and serum proteins. Psoriasis-related cytokine-response pathways are considered in the context of the transcriptome of different mouse models. This approach offers a model for other inflammatory skin and autoimmune diseases.
Collapse
Affiliation(s)
- Michelle A. Lowes
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY 10065
| | - Mayte Suárez-Fariñas
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY 10065
| | - James G. Krueger
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY 10065
| |
Collapse
|
569
|
Research gaps in psoriasis: Opportunities for future studies. J Am Acad Dermatol 2014; 70:146-67. [DOI: 10.1016/j.jaad.2013.08.042] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2013] [Revised: 08/24/2013] [Accepted: 08/26/2013] [Indexed: 02/08/2023]
|
570
|
Hotz C, Valeyrie-Allanore L, Haddad C, Bouvresse S, Ortonne N, Duong T, Ingen-Housz-Oro S, Roujeau J, Wolkenstein P, Chosidow O. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol 2013; 169:1223-32. [DOI: 10.1111/bjd.12502] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/30/2013] [Indexed: 12/18/2022]
Affiliation(s)
- C. Hotz
- Department of Dermatology; Referral Center for Toxic and Autoimmune Blistering Diseases; Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
| | - L. Valeyrie-Allanore
- Department of Dermatology; Referral Center for Toxic and Autoimmune Blistering Diseases; Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
- LIC EA 4393; Assistance Publique-Hôpitaux de Paris (APHP); Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
| | - C. Haddad
- Department of Dermatology; Referral Center for Toxic and Autoimmune Blistering Diseases; Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
| | - S. Bouvresse
- Department of Dermatology; Referral Center for Toxic and Autoimmune Blistering Diseases; Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
| | - N. Ortonne
- Department of Pathology; Assistance Publique - Hôpitaux de Paris (APHP); Université - Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
| | - T.A. Duong
- Department of Dermatology; Referral Center for Toxic and Autoimmune Blistering Diseases; Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
| | - S. Ingen-Housz-Oro
- Department of Dermatology; Referral Center for Toxic and Autoimmune Blistering Diseases; Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
| | - J.C. Roujeau
- Department of Dermatology; Referral Center for Toxic and Autoimmune Blistering Diseases; Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
| | - P. Wolkenstein
- Department of Dermatology; Referral Center for Toxic and Autoimmune Blistering Diseases; Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
- LIC EA 4393; Assistance Publique-Hôpitaux de Paris (APHP); Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
| | - O. Chosidow
- Department of Dermatology; Referral Center for Toxic and Autoimmune Blistering Diseases; Université-Paris-Est Créteil Val de Marne (UPEC); Henri-Mondor Hospital; 51, avenue du Maréchal de Tassigny Créteil CEDEX 94010 France
- INSERM; Centre d'Investigation Clinique 006; APHP; Créteil F-94000 France
| |
Collapse
|
571
|
|
572
|
Abstract
Previous genetic epidemiological studies of psoriasis and alopecia areata demonstrated strong heritability in first-degree relatives and in twins. In recent years, these two conditions have emerged as two skin diseases that are starting to yield their secrets through genome-wide association studies. Both diseases manifest prominent human leukocyte antigen (HLA) associations, psoriasis primarily with major histocompatibility complex (MHC) Class 1, specifically HLA-Cw6, and alopecia areata primarily with MHC Class II. Despite these differences in HLA associations, both diseases have in common a prominent role for CD8+ lymphocytes. The purpose of this brief review is to present the recent developments in the genetics of psoriasis.
Collapse
Affiliation(s)
- James T Elder
- Department of Dermatology, University of Michigan Medical School and Ann Arbor VA Hospital, Ann Arbor, Michigan, USA
| |
Collapse
|
573
|
Les dernières interleukines pour de nouvelles fonctions en rhumatologie : de l’IL-34 à l’IL-38 ou « Les interleukines font leurs grands numéros ». ACTA ACUST UNITED AC 2013. [DOI: 10.1016/j.rhum.2013.04.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
574
|
A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 2013; 10:135-47. [PMID: 24247370 DOI: 10.1038/nrrheum.2013.174] [Citation(s) in RCA: 152] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Autoinflammatory diseases are associated with abnormal activation of the innate immune system, leading to clinical inflammation and high levels of acute-phase reactants. The first group to be identified was the periodic fever diseases, of which familial Mediterranean fever (FMF) is the most common. In FMF, genetic results are not always straightforward; thus, flowcharts to guide the physician in requesting mutation analyses and interpreting the findings are presented in this Review. The other periodic fever diseases, which include cryopyrin-associated periodic syndromes (CAPS), TNF receptor-associated periodic syndrome (TRAPS) and mevalonate kinase deficiency/hyperimmunoglobulin D syndrome (MKD/HIDS), have distinguishing features that should be sought for carefully during diagnosis. Among this group of diseases, increasing evidence exists for the efficacy of anti-IL-1 treatment, suggesting a major role of IL-1 in their pathogenesis. In the past decade, we have started to learn about the other rare autoinflammatory diseases in which fever is less pronounced. Among them are diseases manifesting with pyogenic lesions of the skin and bone; diseases associated with granulomatous lesions; diseases associated with psoriasis; and diseases associated with defects in the immunoproteasome. A better understanding of the pathogenesis of these autoinflammatory diseases has enabled us to provide targeted biologic treatment at least for some of these conditions.
Collapse
|
575
|
IL36RN Mutations in Generalized Pustular Psoriasis: Just the Tip of the Iceberg? J Invest Dermatol 2013; 133:2503-2504. [DOI: 10.1038/jid.2013.361] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
576
|
Pan QZ, Pan K, Zhao JJ, Chen JG, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC. Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma. Cancer Immunol Immunother 2013; 62:1675-85. [PMID: 24061617 PMCID: PMC11029579 DOI: 10.1007/s00262-013-1471-1] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2013] [Accepted: 08/19/2013] [Indexed: 12/17/2022]
Abstract
Interleukin-36α (IL-36α) has been found to have a prominent role in the pathogenesis of inflammatory disorders; however, little is known about the role of IL-36α in cancer. In this study, we investigated the expression, prognostic value, and the underlying antitumor mechanism of IL-36α in hepatocellular carcinoma (HCC). From immunohistochemistry analysis, IL-36α expression was lower in poorly differentiated HCC cells. In clinicopathological analysis, low IL-36α expression significantly correlated with tumor size, histological differentiation, tumor stage, and vascular invasion, and low intratumoral IL-36α expression had significantly worse overall survival rates and shorter disease-free survival rates. Moreover, intratumoral IL-36α expression was an independent risk factor for overall survival. Consecutive sections were used to detect CD3+, CD8+, and CD4+ tumor-infiltrating lymphocytes (TILs), and we found that high-IL-36α-expressing tumor tissues exhibited a significantly higher proportion of intratumoral CD3+ and CD8+ TILs, but not CD4+ TILs. Our in vitro model confirmed that supernatant from IL-36α-overexpressing human HCC cells had an increased capacity to recruit CD3+ and CD8+ T cells. Consistently, mouse HCC cells engineered to overexpress IL-36α demonstrated markedly delayed growth in vivo, as well as higher levels of intratumoral CD3+ and CD8+ TILs, compared with control mice. In vitro chemotaxis analysis also showed that mouse HCC cells overexpressing IL-36α could recruit more number of CD3+ and CD8+ T cells. These results show that IL-36α expression may play a pivotal role in determining the prognosis of patients with HCC, which we attribute to the activation of adaptive T cell immunity, especially CD8+ T cell immune response.
Collapse
Affiliation(s)
- Qiu-Zhong Pan
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Ke Pan
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Jing-Jing Zhao
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Ju-Gao Chen
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Jian-Jun Li
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Lin Lv
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Dan-Dan Wang
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Hai-Xia Zheng
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Shan-Shan Jiang
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Xiao-Fei Zhang
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| | - Jian-Chuan Xia
- State Key Laboratory of Oncology in South China, Department of Biotherapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060 People’s Republic of China
| |
Collapse
|
577
|
Sanchez GAM, de Jesus AA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation. Rheum Dis Clin North Am 2013; 39:701-34. [PMID: 24182851 PMCID: PMC3888876 DOI: 10.1016/j.rdc.2013.08.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The pathogenesis of monogenic autoinflammatory diseases converges on the presence of exaggerated immune responses that are triggered through activation of altered pattern recognition receptor (PRR) pathways and result in cytokine/chemokine amplification loops and the inflammatory clinical phenotype seen in autoinflammatory patients. The PRR response can be triggered by accumulation of metabolites, by mutations in sensors leading to their constitutive overactivation, or by mutations in mediator cytokine pathways that lead to amplification and/or inability to downregulate an inflammatory response in hematopoietic and/or nonhematopoietic cells. The study of the pathogenesis of sterile inflammation in patients with autoinflammatory syndromes continues to uncover novel inflammatory pathways.
Collapse
Affiliation(s)
- Gina A Montealegre Sanchez
- Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Building 10, Room 6D47-B, 10 Center Drive, Bethesda, MD 20892, USA
| | | | | |
Collapse
|
578
|
Sugiura K, Takemoto A, Yamaguchi M, Takahashi H, Shoda Y, Mitsuma T, Tsuda K, Nishida E, Togawa Y, Nakajima K, Sakakibara A, Kawachi S, Shimizu M, Ito Y, Takeichi T, Kono M, Ogawa Y, Muro Y, Ishida-Yamamoto A, Sano S, Matsue H, Morita A, Mizutani H, Iizuka H, Muto M, Akiyama M. The Majority of Generalized Pustular Psoriasis without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist. J Invest Dermatol 2013; 133:2514-2521. [DOI: 10.1038/jid.2013.230] [Citation(s) in RCA: 189] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Revised: 04/22/2013] [Accepted: 04/26/2013] [Indexed: 11/09/2022]
|
579
|
Li M, Han J, Lu Z, Li H, Zhu K, Cheng R, Jiao Q, Zhang C, Zhu C, Zhuang Y, Wang Y, Shi J, Guo Y, Wu R, Yao Z. Prevalent and Rare Mutations in IL-36RN Gene in Chinese Patients with Generalized Pustular Psoriasis and Psoriasis Vulgaris. J Invest Dermatol 2013; 133:2637-2639. [DOI: 10.1038/jid.2013.267] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
580
|
Mutations in IL36RN in Patients with Generalized Pustular Psoriasis. J Invest Dermatol 2013; 133:2634-2637. [DOI: 10.1038/jid.2013.214] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
581
|
Abstract
INTRODUCTION Biological therapies have revolutionized moderate-to-severe psoriasis treatment. Increased understanding of disease pathogenesis has yielded multiple therapeutic targets involving the IL-23/Th17 pathway, while current therapies continue to be monitored for long-term efficacy and safety. AREAS COVERED This review details current understanding of psoriasis immunopathogenesis specifically related to therapeutic targets. Approved and emerging biological psoriasis therapies targeting TNF-α, IL-12/23p40, IL-17 and IL-23p19 are covered. Biological agent uses in special circumstances are reviewed together with the emerging debate on biosimilar therapies and their potential future role in psoriasis and other inflammatory diseases. EXPERT OPINION Psoriasis treatment has expanded and has become more effective due to increased understanding of disease pathogenesis. However, lack of efficacy in select psoriasis patients, safety concerns and limited treatment efficacy in psoriasis variants (e.g., pustular) are areas which still need improvement. As such, pharmacogenomics will be of vital importance in future for individualized psoriasis care. Further, a better understanding of the multiple psoriasis comorbidities, especially cardiovascular disease, continues to be of significant interest in the psoriasis community. Last, the emergence of biosimilar agents has the potential to change psoriasis treatment, especially as it relates to better access for the psoriasis community worldwide.
Collapse
Affiliation(s)
- Bobbak Mansouri
- Dermatology Research FellowBaylor University Medical Center, Division of Dermatology , 3900 Junius Street, Suite 125, Dallas, TX 75204 , USA
| | | | | |
Collapse
|
582
|
Touitou I, Galeotti C, Rossi-Semerano L, Hentgen V, Piram M, Koné-Paut I. The expanding spectrum of rare monogenic autoinflammatory diseases. Orphanet J Rare Dis 2013; 8:162. [PMID: 24131530 PMCID: PMC4016572 DOI: 10.1186/1750-1172-8-162] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Accepted: 10/05/2013] [Indexed: 12/14/2022] Open
Abstract
Monogenic autoinflammatory diseases are a group of hereditary disorders characterized by a clinical and biological inflammatory syndrome in which there is little or no evidence of autoimmunity. The discovery of the first causative gene in 1997 was rapidly followed by the identification of many others from the same group. The mutated proteins can be directly or indirectly involved in the regulation of inflammation. The available literature includes numerous reviews, which address the principle diseases, but we wanted to focus on the most recent rare syndromes. A comprehensive review is thus provided, including taxonomic, genetic, and epidemiological data, along with characteristics defining positive and differential diagnoses and treatment. We believe that this update will assist physicians in correctly naming their patient’s illness. This is an essential step for the effective and targeted management of an orphan disease.
Collapse
Affiliation(s)
- Isabelle Touitou
- Laboratoire de génétique des maladies rares et auto-inflammatoires, CHRU de Montpellier, Montpellier, France.
| | | | | | | | | | | | | |
Collapse
|
583
|
Clavel G, Thiolat A, Boissier MC. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine 2013; 80:449-53. [DOI: 10.1016/j.jbspin.2013.04.014] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/22/2013] [Indexed: 01/02/2023]
|
584
|
Rossi-Semerano L, Piram M, Chiaverini C, De Ricaud D, Smahi A, Koné-Paut I. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 2013; 132:e1043-7. [PMID: 24019411 DOI: 10.1542/peds.2012-3935] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
YM is the first son of Tunisian consanguineous parents who developed, at 2 weeks of life, an erythematous and scaly eruption, with subsequent rapid evolution toward generalized pustular psoriasis. Afterward, cutaneous flares of diffuse erythematous rash and pustules involving the whole body appeared, with a once weekly periodicity. Intense irritability was present during flares without fever. Moreover, since 1 month of age the infant presented with diarrhea, dysphagia, and reduced feeding rate, with failure to thrive. Laboratory tests during acute flares showed marked leukocytosis, thrombocytosis, and anemia without C-reactive protein elevation. Skin biopsy and clinical presentation were consistent with pustular psoriasis; nevertheless, the patient did not respond to high-potency topical corticosteroids and retinoid acid. As the patient presented with repeated skin flares early after birth, as well as serious constitutional distress with failure to thrive, an autoinflammatory syndrome like interleukine-1-receptor antagonist deficiency or interleukin-36-receptor antagonist deficiency (DITRA) was considered. The hypothesis was reinforced by parental consanguinity, and absence of skin lesion improvement under standard topical treatment. Genetic analyses showed a homozygous mutation in the IL36RN gene (L27P), which represents the same mutation recently described in DITRA patients. At age 6 months we started treatment with the recombinant interleukin-1 receptor antagonist anakinra with efficacy both on constitutional symptoms and skin involvement. DITRA is a recently described autoinflammatory disease characterized by repeated flares of generalized pustular psoriasis, high fever, asthenia, and systemic inflammation. We report herein the first exhaustive clinical description of an infant with DITRA who was successfully treated with anakinra.
Collapse
Affiliation(s)
- Linda Rossi-Semerano
- Department of Pediatrics and Pediatric Rheumatology, National Reference Centre for Auto-Inflammatory Diseases, University of Paris SUD, APHP, Hôpital de Bicêtre, 78, rue du Général Leclerc 94275 Le Kremlin-Bicêtre Cedex, France.
| | | | | | | | | | | |
Collapse
|
585
|
Standing A, Omoyinmi E, Brogan P. Gene hunting in autoinflammation. Clin Transl Allergy 2013; 3:32. [PMID: 24070009 PMCID: PMC3849995 DOI: 10.1186/2045-7022-3-32] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Accepted: 09/23/2013] [Indexed: 11/10/2022] Open
Abstract
Steady progress in our understanding of the genetic basis of autoinflammatory diseases has been made over the past 16 years. Since the discovery of the familial Mediterranean fever gene MEFV (also known as marenostrin) in 1997, 18 other genes responsible for monogenic autoinflammatory diseases have been identified to date. The discovery of these genes was made through the utilisation of many genetic mapping techniques, including next generation sequencing platforms. This review article clearly describes the gene hunting approaches, methods of data analysis and the technological platforms used, which has relevance to all those working within the field of gene discovery for Mendelian disorders.
Collapse
Affiliation(s)
- Ariane Standing
- Institute of Child Health, UCL, 30 Guilford Street, London WC1N 1EH, UK.
| | | | | |
Collapse
|
586
|
Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2013; 53:676-84. [PMID: 23967807 DOI: 10.1111/ijd.12070] [Citation(s) in RCA: 138] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Generalized pustular psoriasis (GPP) is a severe but rare variant of psoriasis. Our objective is to review the clinical profile, comorbidities, and outcome of patients with GPP. MATERIALS AND METHODS A retrospective note review of all patients with adult-onset GPP. RESULTS A total of 102 patients with adult-onset GPP were diagnosed between 1989 and November 2011, with a female to male ratio of 2 : 1. The mean age at onset of GPP was 40.9 years (range: 21-81 years). Acute GPP was the most common variant seen (95 cases), followed by four localized variants of GPP and three with annular pustular psoriasis. Fever and painful skin were present in 89% of patients, arthritis in 34.7%, and leukocytosis in 78.4%. Common triggers were systemic steroids (45 cases), pregnancy (17 cases), and upper respiratory tract infections (16 cases). A positive family history of psoriasis and GPP was present in 29% and 11%, respectively. Comorbidities included obesity (42.9%), hypertension (25.7%), hyperlipidemia (25.7%), and diabetes mellitus (23.7%). The mean duration of admission and pustular flare for acute GPP was 10.3 days (range: 3-44 days) and 16 days (range: 7-60 days), respectively. Fifty-four patients responded to systemic retinoid, 21 to methotrexate, eight to cyclosporine, and one to adalimumab, but recurrences were common. CONCLUSIONS Our study confirms the poor response of GPP to currently available anti-psoriatic agents, with frequent flare-ups. There is a need for a more effective targeted therapy for this condition.
Collapse
Affiliation(s)
- Siew Eng Choon
- Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Johor, Malaysia
| | | | | | | | | | | |
Collapse
|
587
|
Kanazawa N, Nakamura T, Mikita N, Furukawa F. NovelIL36RNmutation in a Japanese case of early onset generalized pustular psoriasis. J Dermatol 2013; 40:749-51. [DOI: 10.1111/1346-8138.12227] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2013] [Accepted: 05/26/2013] [Indexed: 11/26/2022]
Affiliation(s)
- Nobuo Kanazawa
- Department of Dermatology; Wakayama Medical University; Wakayama; Japan
| | | | - Naoya Mikita
- Department of Dermatology; Wakayama Medical University; Wakayama; Japan
| | - Fukumi Furukawa
- Department of Dermatology; Wakayama Medical University; Wakayama; Japan
| |
Collapse
|
588
|
van de Veerdonk FL, Netea MG. New Insights in the Immunobiology of IL-1 Family Members. Front Immunol 2013; 4:167. [PMID: 23847614 PMCID: PMC3703542 DOI: 10.3389/fimmu.2013.00167] [Citation(s) in RCA: 116] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2013] [Accepted: 06/12/2013] [Indexed: 12/28/2022] Open
Abstract
The interleukin-1 (IL 1) family of ligands is associated with acute and chronic inflammation, and plays an essential role in the non-specific innate response to infection. The biological properties of IL 1 family ligands are typically pro-inflammatory. The IL 1 family has 11 family members and can be categorized into subfamilies according to the length of their precursor and the length of the propiece for each precursor (Figure 1). The IL 1 subfamily consists of IL 1α, IL 1β, and IL 33, with the longest propieces of the IL 1 family. IL 18 and IL 37 belong to the IL 18 subfamily and contain smaller propieces than IL 1 and IL-33. Since IL 37 binds to the IL 18Rα chain it is part of the IL 18 subfamily, however it remains to be elucidated how the propiece of IL 37 is removed. IL 36α, β, and γ as well as IL 36 Ra belong to the IL 36 subfamily. In addition, IL 38 likely belongs to this family since it has the ability to bind to the IL 36R. The IL 36 subfamily has the shortest propiece. The one member of the IL 1 family that cannot be categorized in these subfamilies is IL 1 receptor antagonist (IL 1Ra), which has a signal peptide and is readily secreted. In the present review we will describe the biological functions of the IL-1F members and new insights in their biology.
Collapse
Affiliation(s)
- Frank L van de Veerdonk
- Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i) , Nijmegen , Netherlands
| | | |
Collapse
|
589
|
|
590
|
Hayem G. Chinese Shar-Pei dogs: A model for human Mediterranean fever? Joint Bone Spine 2013; 80:353-4. [DOI: 10.1016/j.jbspin.2013.03.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/19/2013] [Indexed: 10/26/2022]
|
591
|
|
592
|
Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol 2013; 131:314-23. [PMID: 23374262 DOI: 10.1016/j.jaci.2012.11.051] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2012] [Revised: 11/06/2012] [Accepted: 11/29/2012] [Indexed: 12/28/2022]
Abstract
The characterization of primary immunodeficiencies (PIDs) in human subjects is crucial for a better understanding of the biology of the immune response. New achievements in this field have been possible in light of collaborative studies; attention paid to new phenotypes, infectious and otherwise; improved immunologic techniques; and use of exome sequencing technology. The International Union of Immunological Societies Expert Committee on PIDs recently reported on the updated classification of PIDs. However, new PIDs are being discovered at an ever-increasing rate. A series of 19 novel primary defects of immunity that have been discovered after release of the International Union of Immunological Societies report are discussed here. These new findings highlight the molecular pathways that are associated with clinical phenotypes and suggest potential therapies for affected patients.
Collapse
|
593
|
Gattorno M, Martini A. Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence. ACTA ACUST UNITED AC 2013; 65:1137-47. [PMID: 23400910 DOI: 10.1002/art.37882] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Accepted: 01/17/2013] [Indexed: 02/06/2023]
|
594
|
Vinh DC, Behr MA. Crohn's as an immune deficiency: from apparent paradox to evolving paradigm. Expert Rev Clin Immunol 2013; 9:17-30. [PMID: 23256761 DOI: 10.1586/eci.12.87] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Crohn's disease is often considered an autoimmune condition, based on the observations of a histopathological inflammatory process in the absence of identifiable causal microorganism(s) and that immune-modulating therapeutics result in diminished host-directed inflammatory pathology. However, the evidence for a self-targeted immune response is unproven; thus, the instigating and perpetuating forces that drive this chronic inflammation remain unknown. In recent years, a convergence of findings from different fields of investigation has led to a new paradigm, where Crohn's disease appears to be the consequence of an intrinsic innate immune deficiency. While genomic/postgenomic studies and functional immunologic investigations offer a common perspective, critical details of the processes involved require further elaboration. In this review, we place this new model in the context of the emerging literature on non-HIV immune deficiencies, to compare and contrast what is known about proven intrinsic (primary) immune deficiencies to the nascent understanding of Crohn's disease. We then re-evaluate postgenomic research, looking at the functional importance of Crohn's disease-associated mutations and polymorphisms, to delineate points of consensus and issues requiring further study. We ask whether the immunologic profile can guide predictions as to which microbial triggers could exploit these defects and thereby initiate and/or perpetuate chronic enteritis. Finally, we outline potential clinical implications of this model, from immunologic assessment of patients to the selection of therapeutic interventions.
Collapse
Affiliation(s)
- Donald C Vinh
- Department of Medicine, McGill University Health Centre, Montreal, QC, H3G 1A4, Canada
| | | |
Collapse
|
595
|
Abstract
This article provides a new categorization of inflammatory pustular dermatoses in the context of recent genetic and biological insights. Monogenic diseases with pustular phenotypes are discussed, including deficiency of interleukin 1 receptor antagonist, deficiency of the interleukin 36 receptor antagonist, CARD14-associated pustular psoriasis, and pyogenic arthritis, pyoderma gangrenosum, and acne. How these new genetic advancements may inform how previously described pustular diseases are viewed, including pustular psoriasis and its clinical variants, with a focus on historical classification by clinical phenotype, is also discussed.
Collapse
Affiliation(s)
- Haley B Naik
- Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 12N238, 10 Center Drive, MSC 1908, Bethesda, MD 20892-1908, USA
| | | |
Collapse
|
596
|
Abstract
Psoriasis is a common yet complex inflammatory dermatosis that may be seen in infants, children, and adolescents. The clinical presentation and course may be quite variable, and while patients with mild disease are often easily managed, those with recalcitrant or more severe disease often present a therapeutic dilemma given the number of therapies available and the relative lack of data on the efficacy and safety of use of these therapies in children. This review presents the reader with an overview of the current understanding of the pathophysiology, diagnosis, and treatment of pediatric psoriasis, with an emphasis on the available data in the literature that pertains to the use in children of currently available topical and systemic therapies, including topical corticosteroids, vitamin D analogs, phototherapy, systemic immunosuppressive medications, and biologic agents.
Collapse
|
597
|
Moll M, Kuemmerle-Deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin Immunol 2013; 147:242-75. [DOI: 10.1016/j.clim.2013.04.008] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2012] [Revised: 04/07/2013] [Accepted: 04/12/2013] [Indexed: 12/20/2022]
|
598
|
Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes. J Invest Dermatol 2013; 133:1366-9. [DOI: 10.1038/jid.2012.490] [Citation(s) in RCA: 114] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
599
|
Almeida de Jesus A, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol 2013; 147:155-74. [PMID: 23711932 DOI: 10.1016/j.clim.2013.03.016] [Citation(s) in RCA: 121] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Revised: 03/29/2013] [Accepted: 03/30/2013] [Indexed: 12/14/2022]
Abstract
The objective of this review is to describe the clinical manifestations of the growing spectrum of monogenic autoinflammatory diseases including recently described syndromes. The autoinflammatory diseases can be grouped based on clinical findings: 1. the three classic hereditary "periodic fever syndromes", familial Mediterranean Fever (FMF); TNF receptor associated periodic syndrome (TRAPS); and mevalonate kinase deficiency/hyperimmunoglobulinemia D and periodic fever syndrome (HIDS); 2. the cryopyrin associated periodic syndromes (CAPS), comprising familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID) or CINCA, and; 3. pediatric granulomatous arthritis (PGA); 4. disorders presenting with skin pustules, including deficiency of interleukin 1 receptor antagonist (DIRA); Majeed syndrome; pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome; deficiency of interleukin 36 receptor antagonist (DITRA); CARD14 mediated psoriasis (CAMPS), and early-onset inflammatory bowel diseases (EO-IBD); 5. inflammatory disorders caused by mutations in proteasome components, the proteasome associated autoinflammatory syndromes (PRAAS) and 6. very rare conditions presenting with autoinflammation and immunodeficiency.
Collapse
Affiliation(s)
- Adriana Almeida de Jesus
- Translational Autoinflammatory Diseases Section, National Institute of Arthritis, Musculoskeletal and Skin diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD 20814, USA
| | | |
Collapse
|
600
|
Petit A. [What's new in clinical dermatology?]. Ann Dermatol Venereol 2013; 139 Suppl 5:S177-87. [PMID: 23522704 DOI: 10.1016/s0151-9638(12)70132-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Medical articles published between September 2011 and September 2012 were selected based on themes related to clinical dermatology. Therapeutics, pediatrics, oncology, sexually transmitted diseases, and major system diseases such as sarcoidosis and connective tissue disease were not retained. The subjects reviewed were: (i) epidemiology, particularly the risks of exposure to infectious agents; (ii) diagnostic tools, dominated by dermoscopy and teledermatology; (iii) the description of new disorders and the reassessment of older diseases; (iv) complementary tests in certain types of dermatosis; (v) a few large "works in progress" in dermatology, where clinical aspects and biological research intertwine and contribute one to the other.
Collapse
Affiliation(s)
- A Petit
- Service de Dermatologie, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| |
Collapse
|